Klin Farmakol Farm. 2004;18(2):124-125

Hodnotenie rizika nesteroidových antiflogistík (Komentár k sérii článkov o NSA)

Milan Kriška1,2
1 Farmakologický ústav Lekárskej fakulty UK, Bratislava
2 Nemocnica s poliklinikou Považská Bystrica

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kriška M. Hodnotenie rizika nesteroidových antiflogistík (Komentár k sérii článkov o NSA). Klin Farmakol Farm. 2004;18(2):124-125.

(Komentár k sérii článkov o NSA)

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tegzová a spol. Nežádoučí účinky léků používaných v revmatologii a základní principy jejich bezpečnosti - II. biologické léky, kortikosteroidy, antiporotika. V tisku.
    2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bossi Ferraz M, Hawkey ChJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 2000; 343: 1520-1528. Go to original source... Go to PubMed...
    3. Lanas a spol. Effects of Nitrate and prophylactic aspirin on upper gastrointestinal bleeding: a retrospective case control study. J. internat. Med. research, 1998; 26: 120-28. Go to original source... Go to PubMed...
    4. Masferrer JL, Seibert K, Yweifel B, Needleman P. Endogeneous glucocorticoids regulate an inducible cyclooxigenase enzyme. Proc. Natl. Acad. Sci. USA, 1992; 89: 3917-3921. Go to original source... Go to PubMed...
    5. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 1990; 86: 1375-1379. Go to original source... Go to PubMed...
    6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286, 2001; 964-959. Go to original source... Go to PubMed...
    7. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000; 284: 1247-1255. Go to original source... Go to PubMed...
    8. Anonymus. Improved ADR Reporting. WHO Pharmaceuticals Newsletter, No 1, 2004.
    9. Weber JCP. Epidemiology of adverse react to nosteroidal antiinflammatory drugs. Adv. Inflam. Res. 1984; 6: 1-7.
    10. Whealton a spol. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomised controlled trial of celecoxib and rofecoxib in oleder hypertensive osteoarthritis patients. Am. J. Ther. 2001; 8: 85-95. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.